AUTHOR=van den Berg Gerrit , Lilien Marc R. , Knops Rutger R. G. , van Es Robert J. J. , van Dijk Atty T. H. , Keijzer-Veen Mandy G. 

TITLE=Case report of hypercalcemia-related kidney complications after discontinuation of denosumab

JOURNAL=Frontiers in Pediatrics

VOLUME=Volume 13 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2025.1583240

DOI=10.3389/fped.2025.1583240

ISSN=2296-2360

ABSTRACT=BackgroundThe use of the osteoclastogenesis inhibitor denosumab is increasing in pediatrics, especially in the treatment of giant cell tumor or granuloma of bone or jaw, aneurysmal bone cyst, and other rare bone disorders. Particularly in pediatric patients, adverse kidney effects—such as acute kidney injury (AKI), hypertension, and nephrocalcinosis—are a significant concern that has received little attention.Case-diagnosis/treatmentIn this report, we present three children who developed hypercalcemia-related AKI six months after discontinuation of denosumab treatment. Treatment of the hypercalcemia consisted of hyperhydration, and administration of furosemide, denosumab or bisphosphonate.ConclusionsClinicians should be aware of the side effects of denosumab for at least seven months after discontinuation of denosumab. Early diagnosis and prompt management of hypercalcemia will result in recovery of AKI, however long-term consequences cannot be ruled out.